Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma

Jared A Gollob1, Catherine J Sciambi, Zhiqing Huang

  • 1Division of Medical Oncology and Transplantation, Department of Medicine, Duke University, Durham, NC, USA. gollo001@mc.duke.edu

Cancer Research
|October 6, 2005
PubMed

Insights

Interferon-gamma (IFN-gamma) inhibits melanoma growth by altering gene expression and activating specific signaling pathways. These changes include down-regulating survival genes and up-regulating pro-apoptotic genes, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interferon-gamma (IFN-gamma) exhibits direct anti-melanoma effects.
  • Understanding the molecular mechanisms of IFN-gamma's direct action is crucial for melanoma treatment.

Purpose of the Study:

  • To investigate the molecular basis of IFN-gamma's direct anti-melanoma effects.
  • To identify IFN-gamma-induced changes in gene expression and signaling pathways in human melanoma cells.

Main Methods:

  • Studied three human melanoma cell lines (DM6, DM93, 501mel) resistant to IFN-alpha.
  • Utilized DNA microarray analysis to assess gene expression changes.
  • Analyzed signaling pathway activation, including MAPK pathways.

Main Results:

  • IFN-gamma induced growth inhibition and apoptosis specifically in DM6 cells.
  • Associated gene expression changes included down-regulation of survival/proliferation genes (MITF, SLUG, CDK2) and up-regulation of pro-apoptotic genes (UNC5H2).
  • IFN-gamma triggered delayed activation of ERK, p38, and JNK kinases in DM6 cells, dependent on MEK1 and p38 activation.

Conclusions:

  • IFN-gamma's anti-melanoma effects involve complex gene expression and signaling pathway modulation.
  • Specific pathways and gene targets identified may offer new therapeutic strategies for melanoma.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...